Evotec and Pfizer collaborate to advance drug discovery in France

Hamburg, Germany, 10 July 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.

The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programs.

Dr Matthias Evers, Chief Business Officer at Evotec, commented: “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. France has established a thriving biopharmaceutical ecosystem to which Evotec also contributes with its strong presence with more than 1,000 employees at our French sites, building a strong pipeline of medicines that matter. Focussing on diseases with severe unmet medical need and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D activities.”

Dr Luca Mollo, Vice President and Medical Lead France at Pfizer, commented: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need”.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking-statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Media

Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com

Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com